Clinical outcomes according to treatment group for the MDACC and CGDB immunotherapy cohorts
| MDACC cohort | CGDB immunotherapy cohort | ||||||||||||
| BRAF | Classic EGFR | EGFR exon 20 | HER2 | KRAS | BRAF V600E | BRAF non-V600E | Classic EGFR | EGFR exon 20 | HER2 | KRAS | MET | Fusions | |
| Survival, median (HR; 95% CI) | |||||||||||||
| PFS | 7.4 (0.36; 0.14 to 0.88)* | 1.81 (2.37; 1.51 to 3.72)* | 2.73 (1.28; 0.80 to 2.02) | 1.88 (1.83; 1.03 to 3.26)* | 2.76 (reference) | 9.79 (0.66; 0.40 to 1.09) | 5.42 (0.83; 0.54 to 1.28) | 2.46 (1.72; 1.22 to 2.43)* | 3.68 (1.31; 0.86 to 1.98) | 3.02 (1.40; 0.84 to 2.36) | 3.71 (reference) | 2.69 (1.13; 0.69 to 1.84) | 2.73 (1.53; 0.96 to 2.44) |
| OS | 35.6 (0.65; 0.26 to 1.63) | 11.3 (2.01; 1.22 to 3.31)* | 22.6 (0.78; 0.44 to 1.39) | 16.8 (1.40; 0.73 to 2.69) | 16.8 (reference) | 20.83 (0.79; 0.50 to 1.24) | 14.88 (0.86; 0.57 to 1.32) | 6.83 (1.33; 0.96 to 1.84) | 10.22 (1.19; 0.83 to 1.73) | 10.81 (1.00; 0.58 to 1.75) | 11.24 (reference) | 12.25 (0.77; 0.47 to 1.28) | 11.60 (0.84; 0.52 to 1.35) |
| ORR, n (%) | |||||||||||||
| Complete/partial response | 5 (62) | 1 (4) | 2 (10) | 1 (8) | 17 (24) | NA | NA | NA | NA | NA | NA | NA | NA |
| Stable disease | 2 (25) | 2 (9) | 5 (25) | 3 (25) | 15 (21) | NA | NA | NA | NA | NA | NA | NA | NA |
| Progressive disease | 1 (12) | 19 (86) | 13 (65) | 8 (67) | 38 (54) | NA | NA | NA | NA | NA | NA | NA | NA |
*p<0.05 versus KRAS.
NA, not available; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.